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Dear Sir,
We read with interest the comments of Dr. Tfelt-Hansen
[1] on the two recently published randomized controlled
trials comparing patients’ preference (primary end-point)
and efficacy (secondary end-points) of frovatriptan with
respect to rizatriptan [2] and almotriptan [3]. In both
studies, frovatriptan showed similar preference and short-
term efficacy outcomes (pain relief and pain free episodes
at 2 h) with respect to the other two triptans.
The principal concern of Dr. Tfelt-Hansen was the very
early use of frovatriptan in these studies, making their
results hardly comparable with those of previous random-
ized controlled trials [4–6], where patients waited until the
headache was moderate or severe. In our studies [2, 3],
patients were instructed to take one dose of study medi-
cation as early as possible after the onset of migraine and to
treat at least 1 out of three attacks, but severity of headache
at the time of drug intake was in the majority of patients
moderate or severe. As a matter of fact, in the study by
Savi et al. [2] 78% of attacks treated with frovatriptan and
74% of those treated with rizatriptan were of moderate or
severe intensity. In the study by Bartolini et al. [3] 80% of
overall treated attacks were of moderate or severe intensity
and 97% of patients had at least one moderate or severe
attack.
However, these studies had a cross-over design and thus
the same patient was treated with both drugs in a randomized
sequence. Moreover, early treatment in our studies better
reflects reality compared to the artificial design of other
studies where patients usually start treatment when the attack
intensity becomes moderate or severe. Thus, the results of
our studies are much more consistent than those of ran-
domized controlled studies with a parallel group design.
In addition, the most significant result of our studies was a
more sustained relieving effect on migraine symptoms with
frovatriptan, with lower headache recurrence rates over the
48 h; these results are in line with previous reports com-
paring frovatriptan with placebo [7–9] or sumatriptan [10].
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